Frontlight ResearchEarly access
Taking people in FinlandPhase 2
Tests estradiol patches and exercise for side effects of prostate cancer hormone therapy
Tests estradiol patches to ease sexual side effects in men with prostate cancer.
Key facts
- Who runs it
- Varsinais-Suomen hyvinvointialue
- Where
- Jyvaskyla, Tampere, and Turku, FinlandSee the 4 sites
- Trial code
- Registry title
- Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTRACISE)
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 310 people, planned
- Started
- 1 Sept 2024
- Expected to end
- 31 Dec 2028
- Type of study
- Interventional
- Record updated
- 7 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with prostate cancer that has not spread, who are starting radiotherapy together with hormone treatment (ADT) for at least one year.
- Age
- Over 18 years.
- Sex
- Men only.
- Disease stage
- Localized prostate cancer, not low-risk, with no distant metastasis in bone, lymph nodes or soft tissue.
- Earlier treatment
- Starting radiotherapy with adjuvant ADT for at least one year. No ongoing glucocorticoid treatment.
Main reasons for not taking part
- Low-risk prostate cancer
- Diabetes mellitus
- Past or current venous thromboembolism, or a heart event or stroke in the last 12 months
- Cardiac pacemaker
- Allergy to estradiol or leuprorelin, or a condition or medicine that rules out estradiol or leuprorelin
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Men with localized PCa starting radiotherapy with adjuvant ADT at least for one year
- Adults (age over 18 years)
- Sufficient performance status ECOG 0-1
- Willingness to participate and signed consent
- Body mass index between 18.5 – 30.0
Who cannot take part
- Prior cardiovascular event or stroke (<12 months)
- Concurrent glucocorticoid treatment
- Known allergy to estradiol or leuprorelin
- Cardiac pacemaker
- Diabetes Mellitus
- Past or current venous thromboembolism
- Other untreated or unstable malignancy in risk of recurrence/progression (as judged by the treating physician)
- Any medication or condition considered as a contraindication to estradiol (allergy to adjuvant compounds (carbomer, trolamine), history with thromboembolic disorders (protein C, protein S, or antithrombin deficiency), porphyria, acute or previous liver disease, drugs with cytochrome P450 enzyme metabolism (anticonvulsants: phenobarbital, phenytoin, carbamazepine; anti-infectives: rifampicin, rifapentine, nevirapine, efavirenz; and St. John's wort)) or leuprorelin (allergy to adjuvant compounds (polylactic acid), Qt-time prolonging drugs (quinidine, disopyramide, amiodarone, sotalol, dofetilide, ibutilide, methadone, moxifloxacin, antipsychotics)
- Patients with low-risk PCa
- Physical disabilities for regular exercise
- Expected poor compliance or expected survival time of less than one year
- Patients with expected adjuvant ADT for less than one year
- Distant bone, lymph node, or soft tissue metastasis
Where in Finland
- Central Finland Hospital District Central Finland Hospital NovaJyvaskyla, FinlandTaking people
- University Of JyvaskylaJyvaskyla, FinlandTaking people
- Tampere University HospitalTampere, FinlandTaking people
- Varsinais-Suomen hyvinvointialueTurku, FinlandTaking people
About the trial
What the trial wants to find out
To estimate the efficacy of E2 in improving sexual dysfunction during ADT.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Transdermal estradiol and exercise in mitigating adverse effects of androgen deprivation therapy for prostate cancer radiation therapy (ESTRACISE)
- Plain-language title
- Tests estradiol patches and exercise for side effects of prostate cancer hormone therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 7 October 2026